Nonalcoholic Fatty Liver Disease Is Associated With Coronary Artery Calcification Development: A Longitudinal Study

Context:Nonalcoholic fatty liver disease (NAFLD) is associated with coronary artery calcification (CAC) in cross-sectional studies. However, whether NAFLD itself affects CAC development or progression remains unknown.Objective:This study investigated the longitudinal association between NAFLD and CA...

Full description

Saved in:
Bibliographic Details
Published inThe journal of clinical endocrinology and metabolism Vol. 101; no. 8; pp. 3134 - 3143
Main Authors Park, Hyo Eun, Kwak, Min-Sun, Kim, Donghee, Kim, Min-Kyung, Cha, Myung-jin, Choi, Su-Yeon
Format Journal Article
LanguageEnglish
Published United States Oxford University Press 01.08.2016
Copyright by The Endocrine Society
Subjects
Online AccessGet full text
ISSN0021-972X
1945-7197
1945-7197
DOI10.1210/jc.2016-1525

Cover

Loading…
Abstract Context:Nonalcoholic fatty liver disease (NAFLD) is associated with coronary artery calcification (CAC) in cross-sectional studies. However, whether NAFLD itself affects CAC development or progression remains unknown.Objective:This study investigated the longitudinal association between NAFLD and CAC score.Design and Setting:This study is a longitudinal cohort study performed in a healthcare center.Participants:Among 1732 subjects who underwent serial CAC evaluation, we evaluated 846 subjects with NAFLD and 886 subjects without NAFLD, as diagnosed via ultrasonography.Main Outcome Measures:CAC score was compared at baseline and follow-up. In subjects without calcification (CAC score = 0) at baseline, any incidental calcification (CAC score >0) at follow-up was defined as development of CAC. In subjects with CAC (CAC score > 0) at baseline, confirmed CAC aggravation was defined as progression. Logistic regression analysis was performed.Results:More subjects with NAFLD than without showed CAC development or progression (48.8 vs 38.4%; P < .001). The impact of NAFLD on a change in CAC score significantly differed according to the CAC score at baseline. In subjects without calcification at baseline, NAFLD significantly affected the development of calcification (odds ratio, 1.49; 95% confidence interval, 1.01–2.21; P = .045) after adjusting for traditional metabolic risk factors. However, in subjects with baseline CAC, NAFLD did not significantly affect progression (P = .734). Additionally, the severity of NAFLD was important. The severity of NAFLD was dose-dependently associated with the development of CAC (P for trend = .043).Conclusions:NAFLD plays a role in the early development of CAC, but not the progression. Ultrasonographic severity of NAFLD is dose-dependently associated with CAC development in subjects with a CAC score of 0 at baseline, independent of traditional risk factors.We investigated the association between NAFLD and CAC. NAFLD significantly affected the development of CAC, but not the progression. The severity of NAFLD was also associated with CAC development.
AbstractList Nonalcoholic fatty liver disease (NAFLD) is associated with coronary artery calcification (CAC) in cross-sectional studies. However, whether NAFLD itself affects CAC development or progression remains unknown. This study investigated the longitudinal association between NAFLD and CAC score. This study is a longitudinal cohort study performed in a healthcare center. Among 1732 subjects who underwent serial CAC evaluation, we evaluated 846 subjects with NAFLD and 886 subjects without NAFLD, as diagnosed via ultrasonography. CAC score was compared at baseline and follow-up. In subjects without calcification (CAC score = 0) at baseline, any incidental calcification (CAC score >0) at follow-up was defined as development of CAC. In subjects with CAC (CAC score > 0) at baseline, confirmed CAC aggravation was defined as progression. Logistic regression analysis was performed. More subjects with NAFLD than without showed CAC development or progression (48.8 vs 38.4%; P < .001). The impact of NAFLD on a change in CAC score significantly differed according to the CAC score at baseline. In subjects without calcification at baseline, NAFLD significantly affected the development of calcification (odds ratio, 1.49; 95% confidence interval, 1.01-2.21; P = .045) after adjusting for traditional metabolic risk factors. However, in subjects with baseline CAC, NAFLD did not significantly affect progression (P = .734). Additionally, the severity of NAFLD was important. The severity of NAFLD was dose-dependently associated with the development of CAC (P for trend = .043). NAFLD plays a role in the early development of CAC, but not the progression. Ultrasonographic severity of NAFLD is dose-dependently associated with CAC development in subjects with a CAC score of 0 at baseline, independent of traditional risk factors.
Nonalcoholic fatty liver disease (NAFLD) is associated with coronary artery calcification (CAC) in cross-sectional studies. However, whether NAFLD itself affects CAC development or progression remains unknown.CONTEXTNonalcoholic fatty liver disease (NAFLD) is associated with coronary artery calcification (CAC) in cross-sectional studies. However, whether NAFLD itself affects CAC development or progression remains unknown.This study investigated the longitudinal association between NAFLD and CAC score.OBJECTIVEThis study investigated the longitudinal association between NAFLD and CAC score.This study is a longitudinal cohort study performed in a healthcare center.DESIGN AND SETTINGThis study is a longitudinal cohort study performed in a healthcare center.Among 1732 subjects who underwent serial CAC evaluation, we evaluated 846 subjects with NAFLD and 886 subjects without NAFLD, as diagnosed via ultrasonography.PARTICIPANTSAmong 1732 subjects who underwent serial CAC evaluation, we evaluated 846 subjects with NAFLD and 886 subjects without NAFLD, as diagnosed via ultrasonography.CAC score was compared at baseline and follow-up. In subjects without calcification (CAC score = 0) at baseline, any incidental calcification (CAC score >0) at follow-up was defined as development of CAC. In subjects with CAC (CAC score > 0) at baseline, confirmed CAC aggravation was defined as progression. Logistic regression analysis was performed.MAIN OUTCOME MEASURESCAC score was compared at baseline and follow-up. In subjects without calcification (CAC score = 0) at baseline, any incidental calcification (CAC score >0) at follow-up was defined as development of CAC. In subjects with CAC (CAC score > 0) at baseline, confirmed CAC aggravation was defined as progression. Logistic regression analysis was performed.More subjects with NAFLD than without showed CAC development or progression (48.8 vs 38.4%; P < .001). The impact of NAFLD on a change in CAC score significantly differed according to the CAC score at baseline. In subjects without calcification at baseline, NAFLD significantly affected the development of calcification (odds ratio, 1.49; 95% confidence interval, 1.01-2.21; P = .045) after adjusting for traditional metabolic risk factors. However, in subjects with baseline CAC, NAFLD did not significantly affect progression (P = .734). Additionally, the severity of NAFLD was important. The severity of NAFLD was dose-dependently associated with the development of CAC (P for trend = .043).RESULTSMore subjects with NAFLD than without showed CAC development or progression (48.8 vs 38.4%; P < .001). The impact of NAFLD on a change in CAC score significantly differed according to the CAC score at baseline. In subjects without calcification at baseline, NAFLD significantly affected the development of calcification (odds ratio, 1.49; 95% confidence interval, 1.01-2.21; P = .045) after adjusting for traditional metabolic risk factors. However, in subjects with baseline CAC, NAFLD did not significantly affect progression (P = .734). Additionally, the severity of NAFLD was important. The severity of NAFLD was dose-dependently associated with the development of CAC (P for trend = .043).NAFLD plays a role in the early development of CAC, but not the progression. Ultrasonographic severity of NAFLD is dose-dependently associated with CAC development in subjects with a CAC score of 0 at baseline, independent of traditional risk factors.CONCLUSIONSNAFLD plays a role in the early development of CAC, but not the progression. Ultrasonographic severity of NAFLD is dose-dependently associated with CAC development in subjects with a CAC score of 0 at baseline, independent of traditional risk factors.
Context:Nonalcoholic fatty liver disease (NAFLD) is associated with coronary artery calcification (CAC) in cross-sectional studies. However, whether NAFLD itself affects CAC development or progression remains unknown.Objective:This study investigated the longitudinal association between NAFLD and CAC score.Design and Setting:This study is a longitudinal cohort study performed in a healthcare center.Participants:Among 1732 subjects who underwent serial CAC evaluation, we evaluated 846 subjects with NAFLD and 886 subjects without NAFLD, as diagnosed via ultrasonography.Main Outcome Measures:CAC score was compared at baseline and follow-up. In subjects without calcification (CAC score = 0) at baseline, any incidental calcification (CAC score >0) at follow-up was defined as development of CAC. In subjects with CAC (CAC score > 0) at baseline, confirmed CAC aggravation was defined as progression. Logistic regression analysis was performed.Results:More subjects with NAFLD than without showed CAC development or progression (48.8 vs 38.4%; P < .001). The impact of NAFLD on a change in CAC score significantly differed according to the CAC score at baseline. In subjects without calcification at baseline, NAFLD significantly affected the development of calcification (odds ratio, 1.49; 95% confidence interval, 1.01–2.21; P = .045) after adjusting for traditional metabolic risk factors. However, in subjects with baseline CAC, NAFLD did not significantly affect progression (P = .734). Additionally, the severity of NAFLD was important. The severity of NAFLD was dose-dependently associated with the development of CAC (P for trend = .043).Conclusions:NAFLD plays a role in the early development of CAC, but not the progression. Ultrasonographic severity of NAFLD is dose-dependently associated with CAC development in subjects with a CAC score of 0 at baseline, independent of traditional risk factors.
Context:Nonalcoholic fatty liver disease (NAFLD) is associated with coronary artery calcification (CAC) in cross-sectional studies. However, whether NAFLD itself affects CAC development or progression remains unknown.Objective:This study investigated the longitudinal association between NAFLD and CAC score.Design and Setting:This study is a longitudinal cohort study performed in a healthcare center.Participants:Among 1732 subjects who underwent serial CAC evaluation, we evaluated 846 subjects with NAFLD and 886 subjects without NAFLD, as diagnosed via ultrasonography.Main Outcome Measures:CAC score was compared at baseline and follow-up. In subjects without calcification (CAC score = 0) at baseline, any incidental calcification (CAC score >0) at follow-up was defined as development of CAC. In subjects with CAC (CAC score > 0) at baseline, confirmed CAC aggravation was defined as progression. Logistic regression analysis was performed.Results:More subjects with NAFLD than without showed CAC development or progression (48.8 vs 38.4%; P < .001). The impact of NAFLD on a change in CAC score significantly differed according to the CAC score at baseline. In subjects without calcification at baseline, NAFLD significantly affected the development of calcification (odds ratio, 1.49; 95% confidence interval, 1.01–2.21; P = .045) after adjusting for traditional metabolic risk factors. However, in subjects with baseline CAC, NAFLD did not significantly affect progression (P = .734). Additionally, the severity of NAFLD was important. The severity of NAFLD was dose-dependently associated with the development of CAC (P for trend = .043).Conclusions:NAFLD plays a role in the early development of CAC, but not the progression. Ultrasonographic severity of NAFLD is dose-dependently associated with CAC development in subjects with a CAC score of 0 at baseline, independent of traditional risk factors.We investigated the association between NAFLD and CAC. NAFLD significantly affected the development of CAC, but not the progression. The severity of NAFLD was also associated with CAC development.
CONTEXT:Nonalcoholic fatty liver disease (NAFLD) is associated with coronary artery calcification (CAC) in cross-sectional studies. However, whether NAFLD itself affects CAC development or progression remains unknown. OBJECTIVE:This study investigated the longitudinal association between NAFLD and CAC score. DESIGN AND SETTING:This study is a longitudinal cohort study performed in a healthcare center. PARTICIPANTS:Among 1732 subjects who underwent serial CAC evaluation, we evaluated 846 subjects with NAFLD and 886 subjects without NAFLD, as diagnosed via ultrasonography. MAIN OUTCOME MEASURES:CAC score was compared at baseline and follow-up. In subjects without calcification (CAC score = 0) at baseline, any incidental calcification (CAC score >0) at follow-up was defined as development of CAC. In subjects with CAC (CAC score > 0) at baseline, confirmed CAC aggravation was defined as progression. Logistic regression analysis was performed. RESULTS:More subjects with NAFLD than without showed CAC development or progression (48.8 vs 38.4%; P < .001). The impact of NAFLD on a change in CAC score significantly differed according to the CAC score at baseline. In subjects without calcification at baseline, NAFLD significantly affected the development of calcification (odds ratio, 1.49; 95% confidence interval, 1.01–2.21; P = .045) after adjusting for traditional metabolic risk factors. However, in subjects with baseline CAC, NAFLD did not significantly affect progression (P = .734). Additionally, the severity of NAFLD was important. The severity of NAFLD was dose-dependently associated with the development of CAC (P for trend = .043). CONCLUSIONS:NAFLD plays a role in the early development of CAC, but not the progression. Ultrasonographic severity of NAFLD is dose-dependently associated with CAC development in subjects with a CAC score of 0 at baseline, independent of traditional risk factors.We investigated the association between NAFLD and CAC. NAFLD significantly affected the development of CAC, but not the progression. The severity of NAFLD was also associated with CAC development.
Author Kim, Min-Kyung
Cha, Myung-jin
Choi, Su-Yeon
Park, Hyo Eun
Kwak, Min-Sun
Kim, Donghee
AuthorAffiliation Department of Internal Medicine, Healthcare System Gangnam Center, Seoul National University Hospital, 135-984 Seoul, Korea
AuthorAffiliation_xml – name: Department of Internal Medicine, Healthcare System Gangnam Center, Seoul National University Hospital, 135-984 Seoul, Korea
Author_xml – sequence: 1
  givenname: Hyo Eun
  surname: Park
  fullname: Park, Hyo Eun
  organization: 1Department of Internal Medicine, Healthcare System Gangnam Center, Seoul National University Hospital, 135-984 Seoul, Korea
– sequence: 2
  givenname: Min-Sun
  surname: Kwak
  fullname: Kwak, Min-Sun
  organization: 1Department of Internal Medicine, Healthcare System Gangnam Center, Seoul National University Hospital, 135-984 Seoul, Korea
– sequence: 3
  givenname: Donghee
  surname: Kim
  fullname: Kim, Donghee
  email: messmd@chol.com
  organization: 1Department of Internal Medicine, Healthcare System Gangnam Center, Seoul National University Hospital, 135-984 Seoul, Korea
– sequence: 4
  givenname: Min-Kyung
  surname: Kim
  fullname: Kim, Min-Kyung
  organization: 1Department of Internal Medicine, Healthcare System Gangnam Center, Seoul National University Hospital, 135-984 Seoul, Korea
– sequence: 5
  givenname: Myung-jin
  surname: Cha
  fullname: Cha, Myung-jin
  organization: 1Department of Internal Medicine, Healthcare System Gangnam Center, Seoul National University Hospital, 135-984 Seoul, Korea
– sequence: 6
  givenname: Su-Yeon
  surname: Choi
  fullname: Choi, Su-Yeon
  email: sychoi9@gmail.com
  organization: 1Department of Internal Medicine, Healthcare System Gangnam Center, Seoul National University Hospital, 135-984 Seoul, Korea
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27253666$$D View this record in MEDLINE/PubMed
BookMark eNp1ksFvFCEUxompsdvqzbMh8VAPTvtgZmCmt83WapONPajRG6HMG5eVHbbAtNn_XqbbXpqUhDwgv-89-B5H5GDwAxLynsEp4wzO1uaUAxMFq3n9isxYW9WFZK08IDMAzopW8j-H5CjGNQCrqrp8Qw655HUphJiR-N0P2hm_8s4aeqlT2tGlvcNAL2xEHZFeRTqP0RurE3b0t00ruvAhq8KOzkPCHBY5g-2t0cn6gV7gHTq_3eCQzumcLv3w16axs7kO_ZEXu7fkda9dxHeP8Zj8uvzyc_GtWF5_vVrMl4UpW8GLUvSg66bWOr9GVG3PoGFoOqgrIUFquNEd5lOOpq8AG9FoU0kwvENTy16Ux-TTPu82-NsRY1IbGw06pwf0Y1SsgVZAKdiEfnyGrv0Y8o2jKpmoSslbCZn68EiNNxvs1DbYTbZBPdmZAb4HTPAxBuyVsenBlRS0dYqBmnqm1kZNPVNTz7Lo8zPRU94X8GqP33uX3Y__3HiPQa1Qu7RSkEe2pykmATR5V-TJeZad7GV-3L5U4OEPlf8BYb2ylQ
CitedBy_id crossref_primary_10_12998_wjcc_v8_i20_4688
crossref_primary_10_1016_j_abb_2020_108679
crossref_primary_10_1136_openhrt_2021_001850
crossref_primary_10_1371_journal_pone_0301126
crossref_primary_10_1038_s41598_020_61750_4
crossref_primary_10_5812_hepatmon_122772
crossref_primary_10_1016_j_dld_2018_04_027
crossref_primary_10_1007_s12350_019_01783_z
crossref_primary_10_1161_CIRCIMAGING_124_017376
crossref_primary_10_1186_s12872_024_03880_5
crossref_primary_10_1016_j_alcohol_2020_07_010
crossref_primary_10_1371_journal_pone_0224626
crossref_primary_10_1016_j_atherosclerosis_2018_03_027
crossref_primary_10_1007_s11604_021_01113_9
crossref_primary_10_1016_j_atherosclerosis_2016_11_021
crossref_primary_10_3390_life12081189
crossref_primary_10_3390_ijerph16183415
crossref_primary_10_1371_journal_pone_0180118
crossref_primary_10_5009_gnl19069
crossref_primary_10_1007_s12350_019_01736_6
crossref_primary_10_1016_j_cgh_2023_09_018
crossref_primary_10_1016_j_jacc_2018_11_050
crossref_primary_10_1016_j_jhep_2017_09_021
crossref_primary_10_1111_eci_14188
crossref_primary_10_1038_s41598_017_09851_5
crossref_primary_10_1111_apt_17869
crossref_primary_10_1016_S2468_1253_24_00310_8
crossref_primary_10_2174_1381612826666200417142444
crossref_primary_10_3350_cmh_2020_0239
crossref_primary_10_1155_2020_8489238
crossref_primary_10_2478_rjim_2018_0009
crossref_primary_10_1016_j_cpcardiol_2023_102065
crossref_primary_10_15829_1560_4071_2023_5552
crossref_primary_10_1007_s00535_018_1516_5
crossref_primary_10_1186_s12933_022_01725_z
crossref_primary_10_1111_echo_13545
crossref_primary_10_1097_CRD_0000000000000537
crossref_primary_10_1186_s13098_025_01577_z
crossref_primary_10_1016_j_clnesp_2020_03_003
crossref_primary_10_1016_j_dsx_2023_102938
crossref_primary_10_1038_s41598_025_88133_x
crossref_primary_10_14814_phy2_13386
crossref_primary_10_1016_j_cgh_2021_09_021
crossref_primary_10_2147_DMSO_S426102
crossref_primary_10_1136_jech_2018_210943
crossref_primary_10_3390_ijms251910595
crossref_primary_10_34172_mejdd_2020_166
crossref_primary_10_1111_liv_15591
crossref_primary_10_3904_kjim_2017_343
crossref_primary_10_1016_j_dld_2017_12_014
crossref_primary_10_3390_jcm10081569
crossref_primary_10_1371_journal_pone_0202325
ContentType Journal Article
Copyright Copyright © 2016 by the Endocrine Society 2016
Copyright © 2016 by The Endocrine Society
Copyright © 2016 by the Endocrine Society
Copyright_xml – notice: Copyright © 2016 by the Endocrine Society 2016
– notice: Copyright © 2016 by The Endocrine Society
– notice: Copyright © 2016 by the Endocrine Society
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7T5
7TM
H94
K9.
7X8
DOI 10.1210/jc.2016-1525
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Calcium & Calcified Tissue Abstracts
Immunology Abstracts
Nucleic Acids Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Calcium & Calcified Tissue Abstracts
Nucleic Acids Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
AIDS and Cancer Research Abstracts


Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1945-7197
EndPage 3143
ExternalDocumentID 27253666
10_1210_jc_2016_1525
00004678-201608000-00022
10.1210/jc.2016-1525
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-~X
.55
.XZ
08P
0R~
18M
1TH
29K
2WC
34G
354
39C
4.4
48X
53G
5GY
5RS
5YH
8F7
AABZA
AACZT
AAIMJ
AAPQZ
AAPXW
AARHZ
AAUAY
AAVAP
AAWTL
ABBLC
ABDFA
ABEJV
ABGNP
ABJNI
ABLJU
ABMNT
ABNHQ
ABOCM
ABPMR
ABPPZ
ABPQP
ABPTD
ABQNK
ABVGC
ABWST
ABXVV
ACGFO
ACGFS
ACPRK
ACUTJ
ACYHN
ADBBV
ADGKP
ADGZP
ADHKW
ADQBN
ADRTK
ADVEK
AELWJ
AEMDU
AENEX
AENZO
AETBJ
AEWNT
AFCHL
AFFZL
AFGWE
AFOFC
AFRAH
AFXAL
AGINJ
AGKRT
AGQXC
AGUTN
AHMBA
AHMMS
AJEEA
ALMA_UNASSIGNED_HOLDINGS
APIBT
ARIXL
ASPBG
ATGXG
AVWKF
AZFZN
BAWUL
BAYMD
BCRHZ
BEYMZ
BSWAC
BTRTY
C45
CDBKE
CS3
D-I
DAKXR
DIK
E3Z
EBS
EJD
EMOBN
ENERS
F5P
FECEO
FHSFR
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
HZ~
H~9
KBUDW
KOP
KQ8
KSI
KSN
L7B
M5~
MHKGH
MJL
N9A
NLBLG
NOMLY
NOYVH
NVLIB
O9-
OAUYM
OBH
OCB
ODMLO
OFXIZ
OGEVE
OHH
OJZSN
OK1
OPAEJ
OVD
OVIDX
P2P
P6G
REU
ROX
ROZ
TEORI
TJX
TLC
TR2
TWZ
VVN
W8F
WOQ
X7M
YBU
YFH
YHG
YOC
YSK
ZY1
~02
~H1
.GJ
3O-
7X7
88E
8FI
8FJ
AAJQQ
AAKAS
AAPGJ
AAQQT
AAUQX
AAWDT
AAYJJ
ABDPE
ABUWG
ABXZS
ACFRR
ACVCV
ACZBC
ADMTO
ADNBA
ADZCM
AEMQT
AEOTA
AERZD
AFFNX
AFFQV
AFKRA
AFYAG
AGMDO
AGORE
AHGBF
AI.
AJBYB
AJDVS
ALXQX
APJGH
AQDSO
AQKUS
AVNTJ
BENPR
BPHCQ
BVXVI
CCPQU
EIHJH
FEDTE
FYUFA
HMCUK
HVGLF
IAO
IHR
INH
ITC
J5H
M1P
MBLQV
N4W
NU-
OBFPC
PHGZM
PHGZT
PQQKQ
PROAC
PSQYO
TMA
UKHRP
VH1
WHG
X52
ZGI
ZXP
AAYXX
CITATION
3V.
CGR
CUY
CVF
ECM
EIF
NPM
VXZ
7QP
7T5
7TM
H94
K9.
7X8
ID FETCH-LOGICAL-c3962-36f0a585aa197649f1081ecd0546707a0bade9f12ecf40e868ac470c2dec57f63
ISSN 0021-972X
1945-7197
IngestDate Thu Sep 04 18:09:45 EDT 2025
Mon Jun 30 12:45:29 EDT 2025
Wed Feb 19 02:42:38 EST 2025
Tue Jul 01 01:10:41 EDT 2025
Thu Apr 24 23:08:49 EDT 2025
Fri May 16 04:02:33 EDT 2025
Fri Feb 07 10:35:42 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 8
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c3962-36f0a585aa197649f1081ecd0546707a0bade9f12ecf40e868ac470c2dec57f63
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PMID 27253666
PQID 3164372970
PQPubID 2046206
PageCount 10
ParticipantIDs proquest_miscellaneous_1809603616
proquest_journals_3164372970
pubmed_primary_27253666
crossref_citationtrail_10_1210_jc_2016_1525
crossref_primary_10_1210_jc_2016_1525
wolterskluwer_health_00004678-201608000-00022
oup_primary_10_1210_jc_2016-1525
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20160801
2016-August
2016-08-00
PublicationDateYYYYMMDD 2016-08-01
PublicationDate_xml – month: 08
  year: 2016
  text: 20160801
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Washington
PublicationTitle The journal of clinical endocrinology and metabolism
PublicationTitleAlternate J Clin Endocrinol Metab
PublicationYear 2016
Publisher Oxford University Press
Copyright by The Endocrine Society
Publisher_xml – name: Oxford University Press
– name: Copyright by The Endocrine Society
SSID ssj0014453
Score 2.4231045
Snippet Context:Nonalcoholic fatty liver disease (NAFLD) is associated with coronary artery calcification (CAC) in cross-sectional studies. However, whether NAFLD...
CONTEXT:Nonalcoholic fatty liver disease (NAFLD) is associated with coronary artery calcification (CAC) in cross-sectional studies. However, whether NAFLD...
Nonalcoholic fatty liver disease (NAFLD) is associated with coronary artery calcification (CAC) in cross-sectional studies. However, whether NAFLD itself...
SourceID proquest
pubmed
crossref
wolterskluwer
oup
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 3134
SubjectTerms Aged
Calcification
Calcification (ectopic)
Calcinosis - complications
Calcinosis - diagnosis
Calcinosis - epidemiology
Calcinosis - pathology
Coronary artery
Coronary Artery Disease - complications
Coronary Artery Disease - diagnosis
Coronary Artery Disease - epidemiology
Coronary Artery Disease - pathology
Coronary vessels
Disease Progression
Fatty liver
Female
Humans
Liver - diagnostic imaging
Liver diseases
Longitudinal Studies
Male
Middle Aged
Non-alcoholic Fatty Liver Disease - complications
Non-alcoholic Fatty Liver Disease - diagnosis
Non-alcoholic Fatty Liver Disease - epidemiology
Retrospective Studies
Risk factors
Severity of Illness Index
Ultrasonography
Title Nonalcoholic Fatty Liver Disease Is Associated With Coronary Artery Calcification Development: A Longitudinal Study
URI https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00004678-201608000-00022
https://www.ncbi.nlm.nih.gov/pubmed/27253666
https://www.proquest.com/docview/3164372970
https://www.proquest.com/docview/1809603616
Volume 101
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfKkBAIIb4pDGQkeKqM8uE4LW_V2LTBtpdtom-R4zga-0gm0mgqfwZ_MXe2k7qDSsBLVDnXOMr9cr5z7n5HyLsJ12XJ84SJOMwZT1LF5LiQbCxFoUQRysRs6B8cit0T_nmWzAaDn17WUjvPP6gff6wr-R-twhjoFatk_0Gz_UVhAH6DfuEIGobjX-n4EN1o0-L2mxrtyDk41PuYZ4GcmvjZZbTX9M8fHMuvuOe6hZQFmCo3xWTOBRZnmbQ8CwQvh8jWrO_X2NCoLUzzrKOei_ZsCTKPe6Ivs9RVUYM5qpYET5d6DnC76AgLXb21WfgW9Wi7XSYDXMtzm89fsSNv2HZ9_gS3c6r1jVGU_bJo3SLs9jBC0WfQwRJk7e6EJywNbapub5idiEXg2DOzcWh3QH-z_xDAov1HbkqYBXs7-WLw4K4uDRaiNEpiIW6QcJtlvTt1i9yOIPQw7UBmfdoQxJ9J7AoosPrJnwqJpd2fV7yclcpJL4C5R-5f15gT0ZybkgjPsTl-SB64iIROLbwekYGuHpM7By7n4glpfJRRgzJqUEYdyuheQ5coo4gy2qGMWpTRFZRRD2Uf6ZT6GKMGY0_Jyc728dYuc606mIonImKxKAMJkaeUoEPBJ2UIrqZWBQQEIg1SGeSy0DAaaVXyQI_FWCqeBioqtErSUsTPyEZVV_oFobHmQR4FMpgEnOcgy8t4zEMehnFeaqGGZNQ92kw5Hntsp3KRYTwLOsnOVIY6yVAnQ_K-l76y_C1r5ChoaZ0IsyKbnQoz92o1WRzaL99pMCRv-9NgovG7m6x03TYZUuQJ8BRDMSTPrer7iTrADAlbwUJmy6AzE8ODQ8nwNjC6MzwQUfRy7ZVekbvLV2yTbMy_t_o1OM7z_I1B8i9wP8Cr
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Nonalcoholic+Fatty+Liver+Disease+Is+Associated+With+Coronary+Artery+Calcification+Development%3A+A+Longitudinal+Study&rft.jtitle=The+journal+of+clinical+endocrinology+and+metabolism&rft.au=Park%2C+Hyo+Eun&rft.au=Kwak%2C+Min-Sun&rft.au=Kim%2C+Donghee&rft.au=Kim%2C+Min-Kyung&rft.date=2016-08-01&rft.eissn=1945-7197&rft.volume=101&rft.issue=8&rft.spage=3134&rft_id=info:doi/10.1210%2Fjc.2016-1525&rft_id=info%3Apmid%2F27253666&rft.externalDocID=27253666
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-972X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-972X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-972X&client=summon